Full metadata record

DC FieldValueLanguage
dc.contributor.author박진영-
dc.contributor.author조진홍-
dc.contributor.author송은주-
dc.date.accessioned2021-06-09T04:25:27Z-
dc.date.available2021-06-09T04:25:27Z-
dc.date.issued2020-12-
dc.identifier.citationVOL 43-1161-
dc.identifier.issn0253-6269-
dc.identifier.other55882-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/72261-
dc.description.abstractThe ubiquitin?proteasome system (UPS) plays an important role in the cellular processes for protein quality control and homeostasis. Dysregulation of the UPS has been implicated in numerous diseases, including cancer. Indeed, components of UPS are frequently mutated or abnormally expressed in various cancers. Since Bortezomib, a proteasome inhibitor, received FDA approval for the treatment of multiple myeloma and mantle cell lymphoma, increasing numbers of researchers have been seeking drugs targeting the UPS as a cancer therapeutic strategy. Here, we introduce the essential component of UPS, including ubiquitinating enzymes, deubiquitinating enzymes and 26S proteasome, and we summarize their targets and mechanisms that are crucial for tumorigenesis. In addition, we briefly discuss some UPS inhibitors, which are currently in clinical trials as cancer therapeutics.-
dc.publisherArchives of pharmacal research-
dc.titleUbiquitin-proteasome system (UPS) as a target for anticancer treatment-
dc.typeOther-
dc.relation.page11441161-
Appears in Collections:
KIST Publication > ETC
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE